Vaccinex, Inc. in brief
Vaccinex, Inc. is a listed company in the Biotechnology industry, based in Rochester, New York, USA. Its last known market value was $9 M (January 2024); there is no current figure. In the year to December 2024 it had sales of $1 M and a net loss of $19 M. It employs about 23 people. Its shares trade under the symbol VCNX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Vaccinex, Inc.
We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of Alzheimer’s disease, or AD and as our resources allow, also developing pepinemab for head and neck cancer, and pancreatic cancer. Additionally, third party investigators have studied pepinemab in clinical trials in breast cancer, as well as in “window of opportunity” studies in other indications, including melanoma. We have developed multiple proprietary platform technologies and product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies.
From the company's annual report filed with the US SEC: read the report
Vaccinex, Inc. timeline
- 2002
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 10 August 2018; shares registered for exchange trading on 8 August 2018.
- 2021
- 💰Record revenue of $1 millionFY2021, the highest of the 7 years on record.
Events of Vaccinex, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,877 (Jan 2020) · #4,106 (Jan 2021) · #5,112 (Jan 2022) · #5,023 (Dec 2022) · #5,223 (Jul 2023) · #4,534 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -3105.0%
- Operating margin
- -3123.3%
- Return on equity
- —
- Liabilities / assets
- 195.4%
- Net debt
- $-1M
- Revenue growth
- +5.3%
- R&D / revenue
- 2090.0%
- Revenue per employee
- $26 K
- Profit per employee
- $-810 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $1M | +5.3% | $-19M | $-19M | -3105.0% |
| Dec 2023 | $1M | +103.6% | $-23M | $-20M | -3552.6% |
| Dec 2022 | $0M | -68.9% | $-20M | $-20M | -7078.6% |
| Dec 2021 | $1M | +45.2% | $-22M | $-22M | -2486.7% |
| Dec 2020 | $1M | +19.2% | $-28M | $-29M | -4653.2% |
| Dec 2019 | $1M | -27.8% | $-32M | $-32M | -6126.9% |
| Dec 2018 | $1M | — | $-27M | $-30M | -4100.0% |
| Dec 2017 | — | — | $-21M | $-19M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-16M | $0M | $-16M | $-8.88 | — |
| Dec 2023 | $-21M | $0M | $-21M | $-43.68 | — |
| Dec 2022 | $-19M | $0M | $-19M | $-98.05 | — |
| Dec 2021 | $-25M | $0M | $-25M | $-0.78 | — |
| Dec 2020 | $-29M | $0M | $-29M | $-1.54 | — |
| Dec 2019 | $-31M | $0M | $-31M | $-2.47 | — |
| Dec 2018 | $-25M | $0M | $-26M | $-5.65 | — |
| Dec 2017 | $-21M | $0M | $-21M | $-19.90 | — |
Quarterly results
Latest quarter to Dec 2024: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2024.
SEC filings
- Apr 15, 202510-KAnnual report · period to Dec 2024
- Mar 19, 20258-KCurrent reportDirectors or officers changed
- Mar 7, 20258-KCurrent reportListing notice · Regulation FD disclosure
- Dec 17, 20248-KCurrent reportListing notice · Other events
- Nov 14, 20248-KCurrent reportMaterial agreement · Unregistered share sale
- Nov 14, 202410-QQuarterly report · period to Sep 2024
- Oct 9, 20248-KCurrent reportListing notice
- Sep 19, 20248-KCurrent reportMaterial agreement · Unregistered share sale
- Sep 13, 20248-KCurrent reportDirectors or officers changed
- Aug 20, 20248-KCurrent reportOther events
- Aug 14, 202410-QQuarterly report · period to Jun 2024
- Aug 14, 20248-KCurrent reportRegulation FD disclosure
Official filings of Vaccinex, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-19 M
- Net income
- $-19 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $3 M
- Total liabilities
- $5 M
- Total equity
- $-2 M
As of December-2024
Insider trading at Vaccinex, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Albert FriedbergDirector, 10% owner | Grant or awardindirect | +30,756 | $3.250 | $100 K | 1.05 M | Form 4 |
| filed | Maurice ZaudererPresident and CEO, Director, 10% owner | Grant or awardindirect | +46,153 | $3.250 | $150 K | 297,941 | Form 4 |
| filed | Maurice ZaudererPresident and CEO, Director, 10% owner | Option exerciseindirect | +38,610 | $5.640 | $218 K | 176,748 | Form 4 |
| filed | Albert FriedbergDirector, 10% owner | Option exerciseindirect | +214,286 | $5.640 | $1.2 M | 994,910 | Form 4 |
| filed | Albert FriedbergDirector, 10% owner | Option exerciseindirect | +25,723 | $5.640 | $145 K | 1.02 M | Form 4 |
| filed | Maurice ZaudererPresident and CEO, Director, 10% owner | Option exerciseindirect | +29,557 | $5.640 | $167 K | 206,305 | Form 4 |
| filed | Maurice ZaudererPresident and CEO, Director, 10% owner | Option exerciseindirect | +9,768 | $5.640 | $55 K | 216,073 | Form 4 |
| filed | Maurice ZaudererPresident and CEO, Director, 10% owner | Option exerciseindirect | +35,715 | $5.640 | $201 K | 251,788 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Vaccinex, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-7.14 reverse split ; 1-for-6.67 reverse split
Trading halts
- 2024-12-17 14:35 UTC, code LUDP, resumed 14:40 UTC
Fails to deliver
- : 27 shares at $0.83
- : 999 shares at $1.15
- : 1 shares at $0.70
- : 1 shares at $0.70
- : 100 shares at $0.76
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Vaccinex, Inc. scorecard#
Passes 3 of the 9 checks that could be worked out: strongest in growth (2 of 3), weakest in financial health (1 of 3). Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth2 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-8.88 vs -43.68Diluted EPS -8.88 in fiscal 2024 against -43.68 the year before (report's currency).
- ✓Net income higher than five years earlier-$19 M-$19 M in fiscal 2024 against -$32 M in 2019.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2024.
Profitability0 of 2
- ✗Profitable in the newest year-$19 MNet income -$19 M in fiscal 2024.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.50 at the end of fiscal 2024.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $1 M at the end of fiscal 2024.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year352.4%Diluted shares up 352.4% in fiscal 2024.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Vaccinex, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 0.6+5.4%100% | 0.6+107%100% | 0.3−69.4%100% | 0.9+44.0%100% | 0.6r0.1+19.5%100% | 0.5−27.8%100% | 0.7+704%100% | 0.1—100% | |
| Cost of revenue | — | — | — | — | 0.0−99.0%0.3% | 0.2−80.7%38.0% | 1.0+546%143% | 0.2—178% | |
| Research and development | 13−24.3%2087% | 17+18.6%2908% | 14−18.5%5083% | 17−20.4%1907% | 22−16.1%3448% | 26+14.8%4908% | 22+35.1%3087% | 17—18390% | |
| General and administrative | 6.8−1.3%1130% | 6.9+10.9%1207% | 6.2−0.4%2255% | 6.2−15.9%692% | 7.4+11.0%1185% | 6.7+44.4%1275% | 4.6+3.0%638% | 4.5—4981% | |
| Total costs and expenses | 19−17.6%3217% | 23+16.2%4115% | 20−13.7%7339% | 23−19.2%2599% | 29−11.0%4633% | 33+16.2%6221% | 28+32.1%3868% | 21—23549% | |
| Operating income | −19—−3117% | −23—−4015% | −20—−7239% | −22—−2499% | −28—−4533% | −32—−6121% | −27—−3768% | −21—−23449% | |
| Interest expense and finance costs | 0.0+100%0.3% | 0.0−50.0%0.2% | 0.0−99.8%0.7% | 0.8+65.4%89.9% | 0.5—78.2% | — | 0.4−71.1%54.1% | 1.4—1509% | |
| Other non-operating income (expense) | 0.0−95.5%6.8% | 0.9+881%160% | 0.1+116%33.8% | 0.0—4.8% | −0.0−120%−5.0% | 0.2−7.9%29.1% | 0.2—22.8% | −0.0—−44.4% | |
| Income before tax | −19—−3100% | −20—−3553% | −20—−7205% | −22—−2487% | −29—−4616% | −32—−6092% | −30—−4077% | −19—−20843% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −19—−3100% | −20—−3553% | −20—−7205% | −22—−2487% | −29—−4616% | −32—−6092% | −30—−4077% | −19—−20843% | |
| Minority interests' share of net income | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | −0.0—−41.1% | |
| Net income attributable to shareholders | −19—−3100% | −20—−3553% | −20—−7205% | −22—−2487% | −29—−4616% | −32—−6092% | −30—−4077% | −19—−20802% | |
| Earnings per share, basic | -8.88—— | -43.68—— | -98.05r-0.47—— | -0.78—— | -1.54—— | -2.47—— | -5.65—— | -19.90—— | |
| Earnings per share, diluted | -8.88—— | -43.68—— | -98.05r-0.47—— | -0.78—— | -1.54—— | -2.47—— | -5.65—— | -19.90—— | |
| Shares, weighted average (basic) | 2.1+353%— | 0.5+129%— | 0.2r42−99.3%— | 29—— | — | — | — | — | |
| Shares, weighted average (diluted) | 2.1+353%— | 0.5+129%— | 0.2r42−99.3%— | 29+53.6%— | 19+45.9%— | 13+147%— | 5.2+374%— | 1.1—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 1.1−27.9%42.6% | 1.5−76.0%42.3% | 6.4−25.6%80.1% | 8.6−18.9%87.3% | 11+282%90.5% | 2.8−50.6%60.3% | 5.6+34.4%25.5% | 4.2—75.0% | |
| Short-term investments | — | — | — | — | — | 0−100%0.0% | 14—64.0% | — | |
| Receivables | 0.8−12.8%32.3% | 1.0+449%26.5% | 0.2—2.2% | — | 0.2−82.5%1.3% | 0.9+40.5%19.5% | 0.6+446%2.9% | 0.1—2.1% | |
| Other current assets | 0.6−31.3%22.6% | 0.9−6.5%23.5% | 0.9+11.8%11.4% | 0.8+53.1%8.3% | 0.5+58.6%4.6% | 0.3−68.3%7.3% | 1.1+56.7%4.8% | 0.7—12.1% | |
| Current assets | 2.5−24.4%97.5% | 3.3−55.2%92.2% | 7.5−20.5%93.7% | 9.4−16.7%95.6% | 11+181%96.4% | 4.0−81.3%87.1% | 21+331%97.3% | 5.0—89.2% | |
| Property, plant and equipment | 0.1−52.2%2.5% | 0.1−28.0%3.7% | 0.2−36.4%2.4% | 0.3−28.6%3.0% | 0.4−30.0%3.6% | 0.6−1.7%12.9% | 0.6+0.5%2.7% | 0.6—10.8% | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.1−52.9%4.0% | 0.3+120%3.9% | 0.1—1.4% | — | — | — | — | |
| Total assets | 2.6−28.5%100% | 3.6−54.5%100% | 8.0−19.0%100% | 9.8−15.9%100% | 12+154%100% | 4.6−79.1%100% | 22+295%100% | 5.6—100% | |
| Accounts payable | 4.0+94.0%152% | 2.0+34.3%56.2% | 1.5+43.1%19.0% | 1.1−66.5%10.8% | 3.2−1.2%27.1% | 3.2+38.2%69.7% | 2.3+21.6%10.5% | 1.9—34.3% | |
| Debt due within a year | 0.0−66.7%1.0% | 0.1+1.4%2.1% | 0.10.0%0.9% | 0.1—0.8% | — | — | — | — | |
| Current liabilities | 5.1−14.1%196% | 5.9+133%163% | 2.5+12.5%31.8% | 2.3−82.9%22.9% | 13+91.6%113% | 6.9+2.9%149% | 6.7+60.5%30.4% | 4.2—74.7% | |
| Long-term debt | 0−100%0.0% | 0.0−74.3%0.7% | 0.1−42.3%1.3% | 0.2−84.6%1.8% | 1.1—9.7% | — | — | — | |
| Lease liabilities (non-current) | — | — | 0.1—1.8% | — | — | — | — | — | |
| Total liabilities | 5.1−14.4%196% | 5.9+113%164% | 2.8+14.5%34.9% | 2.4−83.0%24.7% | 14+108%122% | 6.9+2.9%149% | 6.7−9.0%30.4% | 7.3—132% | |
| Retained earnings | −359—−13812% | −340—−9362% | −320—−4007% | −300—−3046% | −277—−2371% | −249—−5400% | −217—−984% | −187—−3359% | |
| Shareholders' equity | — | — | — | 7.4—75.3% | −27—−227% | −26—−570% | −8.6—−39.1% | −125—−2250% | |
| Minority interests | — | — | — | — | 240.0%205% | 240.0%520% | 24+100%109% | 12—215% | |
| Total equity | −2.5—−95.8% | −2.3−145%−63.6% | 5.2−29.9%65.1% | 7.4—75.3% | −2.6—−22.3% | −2.3−115%−49.4% | 15—69.6% | −113—−2036% | |
| Total liabilities and equity | 2.6−28.5%100% | 3.6−54.5%100% | 8.0−19.0%100% | 9.8−15.9%100% | 12+154%100% | 4.6−79.1%100% | 22+295%100% | 5.6—100% | |
| Shares outstanding | 2.7+200%— | 0.9+276%— | 0.2r50−99.2%— | 31+37.6%— | 22+50.4%— | 15+29.7%— | 11+941%— | 1.1—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | — | — | — | — | — | 0.2+11.7%47.6% | 0.2+8.3%30.8% | 0.2—229% | |
| Share-based compensation | 0.3−28.1%56.7% | 0.5−13.0%83.2% | 0.5+0.7%198% | 0.5−26.1%60.1% | 0.7+63.8%117% | 0.4+153%85.5% | 0.2−44.5%24.4% | 0.3—354% | |
| Cash from operating activities | −16—−2693% | −21r−17—−3751% | −19—−6936% | −25—−2811% | −29—−4584% | −31—−5873% | −25—−3491% | −21—−23763% | |
| Capital expenditure | −0.0—−3.7% | −0.1—−11.8% | −0.1—−36.0% | −0.0—−3.6% | −0.3—−46.4% | −0.1—−14.9% | −0.2—−32.5% | −0.1—−75.6% | |
| Cash from investing activities | −0.0—−3.7% | −0.1—−11.8% | −0.1—−36.0% | −0.0—−3.6% | −0.3−102%−46.4% | 14—2691% | −14—−1967% | −0.1—−75.6% | |
| Debt issued | — | — | — | — | 1.1—181% | — | — | — | |
| Debt repaid | −0.1—−12.6% | −0.1—−13.0% | −0.1—−27.3% | −0.0—−1.0% | — | — | — | — | |
| Shares issued | — | 1.3−64.1%224% | 3.6−89.2%1295% | 33+93.2%3650% | 17—2720% | — | — | — | |
| Cash from financing activities | 16−4.9%2626% | 17r12−2.3%2911% | 17−27.2%6173% | 23−36.5%2591% | 37+166%5881% | 14−66.3%2639% | 41+70.8%5657% | 24—26638% | |
| Change in cash | −0.4—−71.2% | −4.9—−852% | −2.2—−799% | −2.0−126%−223% | 7.8—1251% | −2.8−298%−543% | 1.4−42.9%199% | 2.5—2799% | |
| Report | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Dec 31, 2024 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 | Q1 FY2022to Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.6+5.4%100% | 0.2*—100% | 0.1+160%100% | 0.2—100% | 0.1−81.1%100% | 0*−100%— | 0.0−60.0%100% | 0*—— | 0.6—100% | 0.2*—100% | 0.1—100% | — | — | |
| Research and development | 13−24.3%2087% | 2.1*−36.5%1001% | 3.2−27.3%6087% | 3.9−23.5%1666% | 3.4−11.3%3253% | 3.4*−10.3%— | 4.4+27.0%21775% | 5.1+31.4%— | 3.8+28.5%693% | 3.7*—1663% | 3.4—6858% | 3.8—— | 3.0—— | |
| General and administrative | 6.8−1.3%1130% | 1.5*−10.1%689% | 1.4−4.0%2767% | 2.1+3.1%901% | 1.8+4.1%1726% | 1.6*+1.7%— | 1.5+6.1%7495% | 2.0+30.1%— | 1.7+5.9%313% | 1.6*—712% | 1.4—2826% | 1.6—— | 1.6—— | |
| Total costs and expenses | 19−17.6%3217% | 3.6*−27.8%1690% | 4.6−21.4%8854% | 6.0−15.9%2566% | 5.2−6.5%4979% | 5.0*−6.7%— | 5.9+20.9%29270% | 7.1+31.0%— | 5.5+20.5%1007% | 5.3*—2375% | 4.8—9684% | 5.4—— | 4.6—— | |
| Operating income | −19—−3117% | −3.4*—−1590% | −4.6—−8754% | −5.7—−2466% | −5.1—−4879% | −5.0*—— | −5.8—−29170% | −7.1—— | −5.0—−907% | −5.1*—−2275% | −4.8—−9584% | −5.4—— | −4.6—— | |
| Interest expense and finance costs | — | — | — | — | — | 0.0r0*—— | 0r0*−100%0.0% | 0−100%— | 0−100%0.0% | 0*—0.0% | 0.0—2.0% | 0.0—— | 0.0—— | |
| Other non-operating income (expense) | 0.0−95.5%6.8% | 0.0*—13.6% | −0.0−100%−5.8% | 0.0−5.9%6.9% | −0.0−104%−1.0% | −0.1*−227%— | 0.9+2612%4610% | 0.0−10.5%— | 0.0—4.4% | 0.0*—18.2% | 0.0—68.0% | 0.0—— | — | |
| Income before tax | −19—−3100% | −3.4*—−1584% | −5.7—−11023% | −5.6—−2427% | −3.9—−3747% | −3.3*—— | −4.9—−24560% | −7.1—— | −5.0—−902% | −5.1*—−2257% | −4.8—−9518% | −5.4—— | −4.6—— | |
| Income tax | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—— | 0—0.0% | 0—— | 0—0.0% | 0*—0.0% | 0—0.0% | 0—— | 0—— | |
| Net income including minority interests | −19—−3100% | −3.4*—−1584% | −5.7—−11023% | −5.6—−2427% | −3.9—−3747% | −3.3*—— | −4.9—−24560% | −7.1—— | −5.0—−902% | −5.1*—−2257% | −4.8—−9518% | −5.4—— | −4.6—— | |
| Minority interests' share of net income | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—— | 0—— | |
| Net income attributable to shareholders | −19—−3100% | −3.4*—−1584% | −5.7—−11023% | −5.6—−2427% | −3.9—−3747% | −3.3*—— | −4.9—−24560% | −7.1—— | −5.0—−902% | −5.1*—−2257% | −4.8—−9518% | −5.4—— | −4.6—— | |
| Earnings per share, basic | — | — | -2.83—— | -3.10—— | -2.94—— | — | -15.25r-1.09—— | -24.54r-0.12—— | -20.89r-0.10—— | — | -1.67r-0.11—— | -0.13—— | -0.12—— | |
| Earnings per share, diluted | — | — | -2.83—— | -3.10—— | -2.94—— | — | -15.25r-1.09—— | -24.54r-0.12—— | -20.89r-0.10—— | — | -1.67r-0.11—— | -0.13—— | -0.12—— | |
| Shares, weighted average (basic) | — | — | 2.0+529%— | 1.8+532%— | 1.3+459%— | — | 0.3r4.5−88.7%— | 0.3r60−99.3%— | 0.2r50−99.4%— | — | 2.8r43—— | 43—— | 39—— | |
| Shares, weighted average (diluted) | — | — | 2.0+529%— | 1.8+532%— | 1.3+459%— | — | 0.3r4.5−88.7%— | 0.3r60−99.3%— | 0.2r50−99.4%— | — | 2.8r43—— | 43—— | 39—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 1.1—42.6% | 1.1−27.9%42.6% | 2.9+2188%59.9% | 0.2−87.8%9.8% | 3.0−10.6%40.3% | 1.5−76.0%42.3% | 0.1−98.2%5.0% | 1.9−83.3%61.8% | 3.3−80.2%67.9% | 6.4—80.1% | 7.2—83.4% | 11—90.7% | 17—92.7% | |
| Receivables | 0.8—32.3% | 0.8−12.8%32.3% | 1.0+5.6%20.3% | 1.0+9400%44.1% | 2.8—37.7% | 1.0+449%26.5% | 0.9+1766%36.5% | 0.0—0.4% | — | 0.2—2.2% | 0.1—0.6% | — | — | |
| Other current assets | 0.6—22.6% | 0.6−31.3%22.6% | 0.9−25.7%17.6% | 0.9+19.7%38.4% | 1.3+19.8%17.8% | 0.9−6.5%23.5% | 1.1+45.2%44.8% | 0.8−11.7%24.6% | 1.1+13.7%22.4% | 0.9—11.4% | 0.8—9.2% | 0.9—6.8% | 1.0—5.3% | |
| Current assets | 2.5—97.5% | 2.5−24.4%97.5% | 4.8+116%98.0% | 2.2−17.8%93.0% | 7.2+61.9%97.1% | 3.3−55.2%92.2% | 2.2−72.5%86.2% | 2.7−78.2%86.8% | 4.4−75.1%90.3% | 7.5—93.7% | 8.0—93.2% | 12—97.5% | 18—98.0% | |
| Property, plant and equipment | 0.1—2.5% | 0.1−52.2%2.5% | 0.1−50.0%1.7% | 0.1−40.1%4.5% | 0.1−46.9%1.5% | 0.1−28.0%3.7% | 0.2−30.5%6.4% | 0.2−30.3%5.7% | 0.2−19.1%4.2% | 0.2—2.4% | 0.2—2.7% | 0.3—2.0% | 0.3—1.4% | |
| Right-of-use (leased) assets | 0—0.0% | 0−100%0.0% | 0.0−92.0%0.3% | 0.1−74.2%2.5% | 0.1−61.9%1.4% | 0.1−52.9%4.0% | 0.2−46.4%7.3% | 0.2+302%7.4% | 0.3+173%5.5% | 0.3—3.9% | 0.4—4.1% | 0.1—0.5% | 0.1—0.5% | |
| Total assets | 2.6—100% | 2.6−28.5%100% | 4.9+89.8%100% | 2.4−23.3%100% | 7.4+50.5%100% | 3.6−54.5%100% | 2.6−70.3%100% | 3.1−75.5%100% | 4.9−73.0%100% | 8.0—100% | 8.6—100% | 13—100% | 18—100% | |
| Accounts payable | 4.0—152% | 4.0+94.0%152% | 4.9+15.1%100% | 3.2+102%137% | 2.3+113%31.6% | 2.0+34.3%56.2% | 4.2+755%165% | 1.6+507%52.1% | 1.1+85.6%22.3% | 1.5—19.0% | 0.5—5.7% | 0.3—2.1% | 0.6—3.3% | |
| Debt due within a year | 0.0—1.0% | 0.0−66.7%1.0% | 0.0−41.3%0.9% | 0.1−16.0%2.7% | 0.1+1.3%1.0% | 0.1+1.4%2.1% | 0.1+1.4%2.9% | 0.1+1.4%2.4% | 0.1+1.4%1.5% | 0.1—0.9% | 0.1—0.9% | 0.1—0.6% | 0.1—0.4% | |
| Current liabilities | 5.1—196% | 5.1−14.1%196% | 6.2−2.9%127% | 5.2+54.6%221% | 4.7+104%63.9% | 5.9+133%163% | 6.4+220%249% | 3.4+127%110% | 2.3+30.0%47.2% | 2.5—31.8% | 2.0—23.1% | 1.5—11.9% | 1.8—9.8% | |
| Long-term debt | 0—0.0% | 0−100%0.0% | — | — | 0.0−92.7%0.1% | 0.0−74.3%0.7% | 0.0−63.0%1.7% | 0.1−54.3%2.0% | 0.1−47.4%1.7% | 0.1—1.3% | 0.1—1.4% | 0.1—1.1% | 0.2—0.9% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | 0.0−88.8%0.8% | 0.1—2.0% | 0.1—2.1% | 0.1—1.8% | 0.2—2.2% | — | — | |
| Total liabilities | 5.1—196% | 5.1−14.4%196% | 6.2−3.9%127% | 5.2+49.1%221% | 4.7+88.9%64.0% | 5.9+113%164% | 6.4+180%251% | 3.5+115%114% | 2.5+29.1%51.0% | 2.8—34.9% | 2.3—26.6% | 1.6—13.0% | 1.9—10.7% | |
| Retained earnings | −359—−13812% | −359—−13812% | −355—−7317% | −349—−14764% | −344—−4667% | −340—−9362% | −337—−13159% | −332—−10752% | −325—−6632% | −320—−4007% | −315—−3653% | −310—−2465% | −304—−1680% | |
| Total equity | −2.5—−95.8% | −2.5—−95.8% | −1.3—−27.2% | −2.9—−121% | 2.7+10.6%36.0% | −2.3−145%−63.6% | −3.9−161%−151% | −0.4−104%−13.7% | 2.4−85.2%49.0% | 5.2—65.1% | 6.3—73.4% | 11—87.0% | 16—89.3% | |
| Total liabilities and equity | 2.6—100% | 2.6−28.5%100% | 4.9+89.8%100% | 2.4−23.3%100% | 7.4+50.5%100% | 3.6−54.5%100% | 2.6−70.3%100% | 3.1−75.5%100% | 4.9−73.0%100% | 8.0—100% | 8.6—100% | 13—100% | 18—100% | |
| Shares outstanding | 2.7—— | 2.7+200%— | 2.6−46.5%— | — | 1.6r1.6−97.1%— | 0.9+276%— | 4.9−88.6%— | 66+53.9%— | 55+28.6%— | 0.2r50—— | 43—— | 43—— | 43—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.3−28.1%56.7% | 0.1*−45.2%26.8% | 0.1−33.9%146% | 0.1−11.1%48.3% | 0.1−25.6%92.3% | 0.1*−21.2%— | 0.1−14.2%575% | 0.1−8.7%— | 0.1−8.5%23.5% | 0.1*—58.7% | 0.1—268% | 0.1—— | 0.1—— | |
| Cash from operating activities | −16—−2693% | −3.9*—−1846% | −3.2*—−6167% | −4.4*—−1903% | −4.6—−4454% | −7.7r−3.6*—— | −3.1*—−15475% | −5.5*—— | −5.0—−916% | −4.6*—−2044% | −4.1*—−8292% | −5.3*—— | −5.0—— | |
| Capital expenditure | −0.0—−3.7% | 0*—0.0% | −0.0*—−15.4% | −0.0*—−6.0% | 0—0.0% | 0*—— | −0.0*—−90.0% | 0*—— | −0.0—−8.9% | — | −0.0*—−98.0% | — | — | |
| Cash from investing activities | −0.0—−3.7% | 0*—0.0% | −0.0*—−15.4% | −0.0*—−6.0% | 0—0.0% | 0*−100%— | −0.0*—−90.0% | 0*—— | −0.0—−8.9% | 0.0*—0.9% | −0.0*—−98.0% | — | — | |
| Debt repaid | −0.1—−12.6% | −0.0*—−8.5% | −0.0*—−61.5% | −0.0*—−3.0% | −0.0—−18.3% | −0.0*—— | −0.0*—−95.0% | −0.0*—— | −0.0—−3.5% | −0.0*—−8.4% | −0.0*—−38.0% | −0.0*—— | −0.0—— | |
| Shares issued | — | — | — | — | — | 0.0*−75.6%— | 0.1*—590% | — | — | 0.0*—18.2% | 0*—0.0% | 0*—— | 3.5—— | |
| Cash from financing activities | 16−4.9%2626% | 2.1*−76.7%1001% | 5.9*+342%11323% | 1.7*−58.7%728% | 6.1+200%5836% | 9.1r5.0*+141%— | 1.3*—6660% | 4.1*—— | 2.0−84.7%367% | 3.8*—1690% | −0.0*—−38.0% | −0.0*—— | 13—— | |
| Change in cash | −0.4—−71.2% | −1.8*−228%−845% | 2.7*—5140% | −2.7*—−1181% | 1.4—1382% | 1.4*—— | −1.8*—−8905% | −1.4*—— | −3.1−137%−558% | −0.8*—−353% | −4.2*—−8428% | −5.4*—— | 8.2—— | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K/A | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Vaccinex, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 5 · Directors and officers 3 · Material agreement 6 · Unregistered share sale 5 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Mar 19, 2025
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $2 M | Private placement after listing | Under $2 million | 1 | equity, options | SEC |
| Mar 2024 | $1 M | Private placement after listing | Under $2 million | 3 | equity, options | SEC |
| Sep 2020 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Jul 2020 | $4 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Jan 2020 | $7 M | Private placement after listing | $2 to $10 million | 5 | equity | SEC |
| Jul 2019 | $14 M | Private placement after listing | $10 to $50 million | 5 | equity | SEC |
| May 2017 | $6 M | No. 1 | $2 to $10 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Vaccinex, Inc. compares in Biotechnology
- Revenue$1 M · higher than 22% of 647
- Revenue growth5.3% · higher than 50% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Vaccinex, Inc.🇺🇸 | $9 M | — | — | +5.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Employees:
- As of December 31, 2024
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Vaccinex, Inc.? Verify and update this profile — free
Show Vaccinex, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.